Andrea Edginton

Prof. Edginton’s academic research focuses on the development and application of physiologically-based pharmacokinetic (PBPK) models and simulation techniques in both the areas of pharmaceuticals and human health risk assessment. Her research examines how the physiology of sub-populations such as children and patients with disease affect the pharmacokinetics of drugs and how this information can be integrated into PBPK models for the optimization of drug therapy. Prof. Edginton also heads the modeling component of the Web-Accessible Population Pharmacokinetics Service – Hemophilia (WAPPS-Hemo.org) project that uses population pharmacokinetic modeling and Bayesian forecasting for tailoring treatment prophylaxis in persons with hemophilia.

• Development and application of physiologically-based pharmacokinetic (PBPK) models and simulation techniques for the guidance of pharmaceutical dosing
• Population pharmacokinetic modeling and Bayesian forecasting for tailoring treatment prophylaxis in persons with hemophilia
• Clinical Pharmacology

Prof. Andrea Edginton’s research focuses on building virtual organisms to study the pharmacokinetics of drugs and environmental contaminants.; and using PBPK models to scale pharmacokinetics among species (e.g., from rat to human) and within a species (e.g., from healthy adults to children or patients) with an eye toward determining the right dose of medicine or determining differential risks associated with contaminant exposure in human health risk. Her research examines how the physiology of sub-populations, particularly children, affects the pharmacokinetics of drugs and how this information can be integrated into PBPK models for the optimization of drug therapy., Prof. Edginton also heads the modeling component of the Web-Accessible Population Pharmacokinetics Service – Hemophilia (WAPPS-Hemo.org) project that uses population pharmacokinetic modeling and Bayesian forecasting for tailoring treatment prophylaxis in persons with hemophilia.

• 2004 PhD Environmental Toxicology, University of Guelph, Guelph, ON, Canada
• 1998 BSc Environmental Biology, University of Guelph, Guelph, ON, Canada

• 2024 WXN Canada’s Most Powerful Women: Top 100 Award, Executive Leaders
• 2019 Outstanding Performance Award, University of Waterloo
• 2017 AFPC/PEBC Award for Excellence in Research or Innovation in Assessment of Competence, Association of Faculties of Pharmacy of Canada
• 2016 Outstanding Performance Award, University of Waterloo
• 2015 Excellence in Science Teaching Award
• 2013 Outstanding Performance Award, University of Waterloo

• Chair, Executive Committee, School of Pharmacy, University of Waterloo (2015-present)
• Member, School Advisory Committee on Appointments, School of Pharmacy, University of Waterloo (2015-present)
• Board Member, Ontario College of Pharmacists (2021-present)
• Chair, Tenure and Promotion Committee, School of Pharmacy, University of Waterloo (2021-present)
• Member, Public Health Search Committee, Faculty of Health, University of Waterloo (2021-present)
• Board of Directors Member, Centre for Bioengineering and Biotechnology, University of Waterloo (2016-present)

• Cross appointed to Department of Biology

• PHARM 221 - Integrated Patient Focused Care 2
  • Taught in 2019, 2020, 2022
• PHARM 223 - Integrated Patient Focused Care 4
  • Taught in 2021, 2024
• PHARM 224 - Pharmacokinetic Fundamentals
  • Taught in 2019, 2020
• PHARM 320 - Integrated Patient Focused Care 5
  • Taught in 2020
• PHARM 609 - Advanced Pharmacokinetics
  • Taught in 2020

* Only courses taught in the past 5 years are displayed.

• Malik PRV, Yeung CHT, Ismaeil S, Advani U, Djie S, Edginton AN. A Physiological Approach to Pharmacokinetics in Chronic Kidney Disease. J Clin Pharmacol. 2020 Oct;60 Suppl 1:S52-S62. doi: 10.1002/jcph.1713. PMID: 33205424.
• Versloot O, Iserman E, Chelle P, Germini F, Edginton AN, Schutgens RE, Iorio A, Fischer K. Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: data from the WAPPS database. Journal of Thrombosis and Haemostasis. 2021.
• Yu JK, Iorio A, Chelle P, Edginton AN. Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study. Haemophilia. 2021 Mar 2. doi: 10.1111/hae.14292. Epub ahead of print. PMID: 33650745.
• Yeung CHT, Ito S, Autmizguine J, Edginton AN. Incorporating Breastfeeding-Related Variability with Physiologically Based Pharmacokinetic Modeling to Predict Infant Exposure to Maternal Medication Through Breast Milk: a Workflow Applied to Lamotrigine. AAPS J. 2021 May 17;23(4):70. doi: 10.1208/s12248-021-00599-5. PMID: 34002327.
• Hamadeh A, Troutman J, Edginton AN. Assessment of Vehicle Volatility and Deposition Layer Thickness in Skin Penetration Models. Pharmaceutics. 2021 May 28;13(6):807. doi: 10.3390/pharmaceutics13060807. PMID: 34071572.

• Willmann S, Edginton AN, Schmitt W. Verbessertes Verfahren zur zeitlich gesteuerten intravenösen Verabreichung des Narkosemittels Propofol (Improved method and technique for controlled intravenous administration of the sedative propofol). Systems Biology, Bayer Technology Services, Leverkusen, Germany. Wipo Patent WO/2006/133825 (date: 21.12.2006).
• Willmann S, Edginton AN, Hoehn K, Schmitt W. Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis (Method for calculating and providing a drug dose - towards individualized dosing). Systems Biology, Bayer Technology Services, Leverkusen, Germany. Wipo Patent WO/2007/147539 (date: 27.12.2007).

• April 30, 2020: New Hallman Director named for School of Pharmacy
• Fall 2019: A dose of reality